Allspring Global Investments Holdings LLC Grows Stock Holdings in United Therapeutics Corporation $UTHR

Allspring Global Investments Holdings LLC increased its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 39.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 146,524 shares of the biotechnology company's stock after buying an additional 41,739 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.35% of United Therapeutics worth $83,558,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Wellington Management Group LLP boosted its stake in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock valued at $1,189,617,000 after buying an additional 1,042,711 shares during the last quarter. Norges Bank purchased a new stake in United Therapeutics during the fourth quarter valued at $293,418,000. Avoro Capital Advisors LLC lifted its position in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Janus Henderson Group PLC raised its position in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company's stock valued at $387,801,000 after purchasing an additional 341,383 shares during the period. Finally, Baillie Gifford & Co. purchased a new stake in United Therapeutics during the fourth quarter valued at approximately $157,390,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the firm's stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $535.99, for a total transaction of $5,091,905.00. Following the transaction, the chief executive officer owned 40,513 shares of the company's stock, valued at approximately $21,714,562.87. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jan Malcolm sold 325 shares of United Therapeutics stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $550.59, for a total value of $178,941.75. Following the sale, the director owned 450 shares in the company, valued at $247,765.50. This trade represents a 41.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 564,743 shares of company stock valued at $316,423,257. Corporate insiders own 8.60% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on UTHR. Royal Bank Of Canada raised their price objective on United Therapeutics from $701.00 to $704.00 and gave the stock an "outperform" rating in a report on Tuesday, July 7th. Bank of America reduced their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Weiss Ratings restated a "buy (b)" rating on shares of United Therapeutics in a research note on Thursday, June 11th. Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $644.82.

United Therapeutics Trading Up 1.3%

UTHR opened at $535.67 on Friday. The firm has a market cap of $22.74 billion, a price-to-earnings ratio of 19.77, a PEG ratio of 1.77 and a beta of 0.58. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The stock's 50-day moving average price is $552.38 and its 200 day moving average price is $530.14.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analysts' expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm's revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.63 EPS. On average, research analysts forecast that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.